Sarcopenia related to neoadjuvant chemotherapy and perioperative outcomes in resected gastric cancer: A multiinstitutional analysis

Katelin A. Mirkin, Franklyn E. Luke, Alexandra Gangi, Jose M. Pimiento, Daniel Jeong, Christopher S. Hollenbeak, Joyce Wong

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: This study's objective was to evaluate the change in sarcopenia score following neoadjuvant chemotherapy (NAC) and to correlate both sarcopenia and change in score with perioperative outcomes in patients with advanced resected gastric cancer. Methods: Multi-institutional analysis of patients with gastric cancer who underwent NAC and resection from 2000-2015 was performed. Demographic and perioperative data were included. Sarcopenia score was defined as CT measurement of total psoas muscle at L3, stratified by height (m). Sarcopenia was defined as a score < 385 mm2/m2 in women and < 545 mm2/m2 in men. Results: Of 36 patients, 19% were sarcopenic prior to NAC. Following NAC, 31% were sarcopenic, with 14% developing sarcopenia during NAC. One patient (3%) became non-sarcopenic. There were no significant differences in patient, disease, or surgery characteristics between patients who were sarcopenic vs. not. Patients with sarcopenia were more likely to have post-operative complications (P=0.05). There was no significant difference in hospital stay (P=0.7402) or survival (P=0.2317). Conclusions: A significant number of patients with gastric cancer become sarcopenic during NAC. Although patients with sarcopenia were nearly twice as likely to develop post-operative complications, this did not appear to impact length of stay (LOS) or survival

Original languageEnglish (US)
Pages (from-to)589-595
Number of pages7
JournalJournal of Gastrointestinal Oncology
Volume8
Issue number3
DOIs
StatePublished - Jun 1 2017

Fingerprint

Sarcopenia
Stomach Neoplasms
Drug Therapy
Length of Stay
Psoas Muscles
Survival
Demography

All Science Journal Classification (ASJC) codes

  • Oncology
  • Gastroenterology

Cite this

@article{c966ceca404547618a8baaba0e125bbc,
title = "Sarcopenia related to neoadjuvant chemotherapy and perioperative outcomes in resected gastric cancer: A multiinstitutional analysis",
abstract = "Background: This study's objective was to evaluate the change in sarcopenia score following neoadjuvant chemotherapy (NAC) and to correlate both sarcopenia and change in score with perioperative outcomes in patients with advanced resected gastric cancer. Methods: Multi-institutional analysis of patients with gastric cancer who underwent NAC and resection from 2000-2015 was performed. Demographic and perioperative data were included. Sarcopenia score was defined as CT measurement of total psoas muscle at L3, stratified by height (m). Sarcopenia was defined as a score < 385 mm2/m2 in women and < 545 mm2/m2 in men. Results: Of 36 patients, 19{\%} were sarcopenic prior to NAC. Following NAC, 31{\%} were sarcopenic, with 14{\%} developing sarcopenia during NAC. One patient (3{\%}) became non-sarcopenic. There were no significant differences in patient, disease, or surgery characteristics between patients who were sarcopenic vs. not. Patients with sarcopenia were more likely to have post-operative complications (P=0.05). There was no significant difference in hospital stay (P=0.7402) or survival (P=0.2317). Conclusions: A significant number of patients with gastric cancer become sarcopenic during NAC. Although patients with sarcopenia were nearly twice as likely to develop post-operative complications, this did not appear to impact length of stay (LOS) or survival",
author = "Mirkin, {Katelin A.} and Luke, {Franklyn E.} and Alexandra Gangi and Pimiento, {Jose M.} and Daniel Jeong and Hollenbeak, {Christopher S.} and Joyce Wong",
year = "2017",
month = "6",
day = "1",
doi = "10.21037/jgo.2017.03.02",
language = "English (US)",
volume = "8",
pages = "589--595",
journal = "Journal of Gastrointestinal Oncology",
issn = "2078-6891",
publisher = "Pioneer Bioscience Publishing Company (PBPC)",
number = "3",

}

Sarcopenia related to neoadjuvant chemotherapy and perioperative outcomes in resected gastric cancer : A multiinstitutional analysis. / Mirkin, Katelin A.; Luke, Franklyn E.; Gangi, Alexandra; Pimiento, Jose M.; Jeong, Daniel; Hollenbeak, Christopher S.; Wong, Joyce.

In: Journal of Gastrointestinal Oncology, Vol. 8, No. 3, 01.06.2017, p. 589-595.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Sarcopenia related to neoadjuvant chemotherapy and perioperative outcomes in resected gastric cancer

T2 - A multiinstitutional analysis

AU - Mirkin, Katelin A.

AU - Luke, Franklyn E.

AU - Gangi, Alexandra

AU - Pimiento, Jose M.

AU - Jeong, Daniel

AU - Hollenbeak, Christopher S.

AU - Wong, Joyce

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Background: This study's objective was to evaluate the change in sarcopenia score following neoadjuvant chemotherapy (NAC) and to correlate both sarcopenia and change in score with perioperative outcomes in patients with advanced resected gastric cancer. Methods: Multi-institutional analysis of patients with gastric cancer who underwent NAC and resection from 2000-2015 was performed. Demographic and perioperative data were included. Sarcopenia score was defined as CT measurement of total psoas muscle at L3, stratified by height (m). Sarcopenia was defined as a score < 385 mm2/m2 in women and < 545 mm2/m2 in men. Results: Of 36 patients, 19% were sarcopenic prior to NAC. Following NAC, 31% were sarcopenic, with 14% developing sarcopenia during NAC. One patient (3%) became non-sarcopenic. There were no significant differences in patient, disease, or surgery characteristics between patients who were sarcopenic vs. not. Patients with sarcopenia were more likely to have post-operative complications (P=0.05). There was no significant difference in hospital stay (P=0.7402) or survival (P=0.2317). Conclusions: A significant number of patients with gastric cancer become sarcopenic during NAC. Although patients with sarcopenia were nearly twice as likely to develop post-operative complications, this did not appear to impact length of stay (LOS) or survival

AB - Background: This study's objective was to evaluate the change in sarcopenia score following neoadjuvant chemotherapy (NAC) and to correlate both sarcopenia and change in score with perioperative outcomes in patients with advanced resected gastric cancer. Methods: Multi-institutional analysis of patients with gastric cancer who underwent NAC and resection from 2000-2015 was performed. Demographic and perioperative data were included. Sarcopenia score was defined as CT measurement of total psoas muscle at L3, stratified by height (m). Sarcopenia was defined as a score < 385 mm2/m2 in women and < 545 mm2/m2 in men. Results: Of 36 patients, 19% were sarcopenic prior to NAC. Following NAC, 31% were sarcopenic, with 14% developing sarcopenia during NAC. One patient (3%) became non-sarcopenic. There were no significant differences in patient, disease, or surgery characteristics between patients who were sarcopenic vs. not. Patients with sarcopenia were more likely to have post-operative complications (P=0.05). There was no significant difference in hospital stay (P=0.7402) or survival (P=0.2317). Conclusions: A significant number of patients with gastric cancer become sarcopenic during NAC. Although patients with sarcopenia were nearly twice as likely to develop post-operative complications, this did not appear to impact length of stay (LOS) or survival

UR - http://www.scopus.com/inward/record.url?scp=85021147190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021147190&partnerID=8YFLogxK

U2 - 10.21037/jgo.2017.03.02

DO - 10.21037/jgo.2017.03.02

M3 - Article

C2 - 28736646

AN - SCOPUS:85021147190

VL - 8

SP - 589

EP - 595

JO - Journal of Gastrointestinal Oncology

JF - Journal of Gastrointestinal Oncology

SN - 2078-6891

IS - 3

ER -